NeoImmuneTech

Executive Summary

NeoImmuneTech is a clinical-stage biotechnology company pioneering novel T-cell therapies for cancer and infectious diseases. Its platform focuses on modulating T-cell homeostasis to enhance immune responses against tumors and pathogens. The company is headquartered in Rockville, Maryland, and was founded in 2016. As a private entity, NeoImmuneTech has not disclosed its total funding or valuation, but its technology holds promise in the competitive immuno-oncology space. The company's lead candidate is expected to enter or advance in clinical trials, targeting indications with high unmet medical need. With a growing pipeline and potential for partnerships, NeoImmuneTech is positioned to contribute to the next wave of T-cell-based immunotherapies. However, as a clinical-stage company, it faces risks related to trial outcomes, regulatory pathways, and financing.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for lead T-cell therapy candidate45% success
• Q4 2026IND filing for second pipeline asset60% success
• H2 2026Strategic partnership or licensing deal for platform technology35% success